Status
Conditions
Treatments
About
Despite availability of many alternative and conventional weight loss options, the prevalence of obesity increased from 15% in 1993 to 27 in 2015. In 2015, 68% of men and 58% of women in the UK were overweight or obese. Overweight and obesity increase the risk for comorbidities such as hypertension, dyslipidaemia, cardiovascular disease, type 2 diabetes and certain cancers. Hormonal regulation of appetite has been shown to influence body weight and body fat . Gut hormones secreted from the intestine are particularly important both in the regulation of appetite and blood glucose level, and recently the gut hormone Glucagon Like Peptide -1 (GLP-1) has been successfully targeted to treat both type 2 diabetes and obesity. Targeting the gut microbiota has been shown to influence gut hormones, in a way is likely to help treat or prevent obesity and type 2 diabetes. In past decades, considerable attention has been given to investigating the new applications of natural prebiotic polymers on gut microbiota composition. Moreover, recent trend in research indicates a bidirectional communication between the gut microbiota and the central nervous system through the microbiome-gut-brain axis (MGBA).
Therefore an in vivo intervention feeding study is proposed performed with a variety of psychological and nutritional tests aiming to compare io fibrewater with an equivalent placebo control water and also highlight both cognitive function, emotional bias and response to appetite and also metabolic profiles of the gut microbiota.
Full description
Study design: A 30-day placebo-controlled randomised trial study in overweight adults who have not been diagnosed with Diabetes.
Participants: 20 participants will be invited to take part in this study. They will be randomly assigned to treatment (n=10) or control (n=10) groups, where they will consume io Fibrewater or Volvic sugar free Lemon & Lime water for 4 weeks. Both water samples (1 bottle/day) need to be taken with the meals (lunch).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion criteria
Females and males, aged 18 years to 65 years
BMI ≥25 kg/m2 with any of the following:
Not dieting within the last month
not having lost >5% body weight in the previous year
Not increased physical activity levels in the past 2-4 weeks or intending to modify them during the study.
Understands and is willing, able and likely to comply with all study procedures and restriction including being willing to follow the nutritional advice.
Able to eat most everyday foods with no current IBS symptoms.
Habitually consumes three standard meals a day (i.e., breakfast, lunch, and dinner)
Exclusion criteria Current use of prescribed medication for neuropsychiatric disorders or history of neuropsychiatric disorders
Primary purpose
Allocation
Interventional model
Masking
30 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Piril Hepsomali; Adele Costabile
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal